Table 3.
Summary of epileptic features found in patients with MDS reported in the literature and proportion of seizure types in individuals with seizures from prominent case series investigating epilepsy; NR = not reported
| Feature | Males n/N |
Females n/N |
Total n/N (%) |
References |
|---|---|---|---|---|
| Epilepsy/seizures | – | – | 326/619 (53%) | [1–4, 7–23, 25–42, 44–48, 51–55, 57–61, 63, 64, 66–71, 73–80, 82–86, 113] |
| Treatment-refractory seizures | – | – | 100/148 (68%) | [1, 10, 12, 18–20, 28, 33, 37, 40, 41, 43, 44, 51–53, 57, 60, 61, 70, 73, 74, 76, 77, 79, 80] |
| Seizure type | Miguet et al. [77] | Marafi et al. [79]* | Cutri-French et al. [113]* |
|---|---|---|---|
| n/N (%) | n/N (%) | n/N (%) | |
| Generalised | |||
| Tonic–clonic | 19/35 (54%) | 15/22 (68%) | 11/22 (50%) |
| Tonic | NR | 14/22 (63%) | NR |
| Myoclonic | 8/35 (23%) | 14/22 (63%) | 4/22 (18%) |
| Absence | 5/35 (14%) | NR | 5/22 (23%) |
| Atypical | NR | 14/22 (63%) | NR |
| Atonic | 12/35 (34%) | 18/22 (82%) | 7/22 (32%) |
| Focal | |||
| Focal | NR | 8/22 (36%) | 1/22 (5%) |
| Complex | 6/35 (17%) | NR | 6/22 (27%) |
*A proportion of individuals may have been documented in both these case series